<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888108</url>
  </required_header>
  <id_info>
    <org_study_id>M10-338</org_study_id>
    <secondary_id>2008-001477-15</secondary_id>
    <nct_id>NCT00888108</nct_id>
  </id_info>
  <brief_title>Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer</brief_title>
  <official_title>A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination With TaxotereÂ® (Docetaxel) in the Treatment of Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 open-label study evaluating the safety of ABT-263 when combined with a&#xD;
      standard and weekly regimen of docetaxel in subjects who have solid tumors with measurable&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety profile of navitoclax (ABT-263) when administered in combination with a standard and weekly regimen of docetaxel.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Study the pharmacokinetic interaction of navitoclax (ABT-263) and docetaxel</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) of navitoclax (ABT-263) with a standard regimen of docetaxel</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the MTD of both navitoclax and docetaxel with a weekly schedule.</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule in combination with a standard and weekly regimen of docetaxel.</measure>
    <time_frame>Bimonthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding progression free survival</measure>
    <time_frame>Bimonthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding objective response rate</measure>
    <time_frame>Bimonthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding overall survival</measure>
    <time_frame>Bimonthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data regarding duration of overall response</measure>
    <time_frame>Bimonthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary data with Eastern Cooperative Oncology Group (ECOG) performance status</measure>
    <time_frame>Bimonthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate biomarkers</measure>
    <time_frame>Bimonthly</time_frame>
    <description>Define the relationship between disease states, B-Cell Lymphoma 2 (Bcl-2) family protein expression, and potential response to the proposed therapy navitoclax when added to a standard and weekly regimen of docetaxel.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>docetaxel +ABT-263</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-263</intervention_name>
    <description>150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.</description>
    <arm_group_label>docetaxel +ABT-263</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.</description>
    <arm_group_label>docetaxel +ABT-263</arm_group_label>
    <other_name>docetaxel, taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subject must be greater then or equal to 18 years of age.&#xD;
&#xD;
          -  Subject must have a histologically and/or cytologically documented cancer for which&#xD;
             docetaxel has been determined to be an appropriate therapy, per the Investigator.&#xD;
&#xD;
          -  Subject must have evaluable and/or measurable disease by Computed Tomography (CT) or&#xD;
             Magnetic Resonance Imaging (MRI) as defined by RECIST.&#xD;
&#xD;
          -  Subjects with brain metastases must have clinically controlled neurologic symptoms,&#xD;
             defined as surgical excision and/or radiation therapy followed by 21 days of stable&#xD;
             neurologic function and no evidence of CNS disease progression as determined by CT or&#xD;
             MRI within 28 days prior to the first dose of study drug.&#xD;
&#xD;
          -  Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of less&#xD;
             then or equal to 1.&#xD;
&#xD;
          -  Subject must have adequate bone marrow, renal and hepatic function per local&#xD;
             laboratory reference range as follows:&#xD;
&#xD;
               -  Bone marrow: Absolute Neutrophil Count (ANC) greater then or equal to&#xD;
                  1500/microliters; platelets greater then or equal to 150,000/mm^3; hemoglobin&#xD;
                  greater then or equal to 9.0 g/dL;&#xD;
&#xD;
               -  Renal function: Serum creatinine less then or equal 2.0 mg/dL or calculated&#xD;
                  creatinine clearance greater than or equal to 50 mL/min;&#xD;
&#xD;
               -  Hepatic function and enzymes: AST and ALT less then or equal to 1.5 x the upper&#xD;
                  limit of normal (ULN) of institution's normal range, ALP less then or equal to&#xD;
                  2.5 x ULN, and bilirubin less then or equal to 1.0 x ULN. Subjects with bone&#xD;
                  metastasis may have ALP less then or equal to 5.0 x ULN.&#xD;
&#xD;
               -  Coagulation: aPTT and PT not to exceed less than or equal to 1.2 x ULN.&#xD;
&#xD;
          -  Female subjects must be surgically sterile, postmenopausal (for at least one year), or&#xD;
             have negative results for a pregnancy test performed as follows:&#xD;
&#xD;
          -  At Screening via a serum sample obtained within 14 days prior to initial study drug&#xD;
             administration, and&#xD;
&#xD;
          -  Prior to dosing via a urine sample obtained on Cycle 1 Day 1, if it has been greater&#xD;
             then 7 days since obtaining the serum pregnancy test results.&#xD;
&#xD;
          -  Female subjects not surgically sterile or postmenopausal (for at least one year) and&#xD;
             non-vasectomized male subjects must practice at least one of the following methods of&#xD;
             birth control:&#xD;
&#xD;
               -  total abstinence from sexual intercourse (minimum one complete menstrual cycle);&#xD;
&#xD;
               -  vasectomized partner;&#xD;
&#xD;
               -  hormonal contraceptives (oral, parenteral or transdermal) for at least three&#xD;
                  months prior to study drug administration;&#xD;
&#xD;
               -  Double-barrier method (including condoms, contraceptive sponge, diaphragm or&#xD;
                  vaginal ring with spermicidal jellies or cream).&#xD;
&#xD;
          -  The subject, or legal representative, must voluntarily sign and date an informed&#xD;
             consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board&#xD;
             (IRB), prior to the initiation of any screening or study-specific procedures.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  The subject has an underlying, predisposing condition of bleeding or currently&#xD;
             exhibits signs of bleeding. The subject has a recent history of thrombocytopenia&#xD;
             associated with bleeding within 1 year prior to first dose of study drug.&#xD;
&#xD;
          -  The subject is currently receiving or requires anticoagulation therapy or any drugs or&#xD;
             herbal supplements that affect platelet function, with the exception of low-dose&#xD;
             anticoagulation medications (i.e., Heparin) that are used to maintain the patency of a&#xD;
             central intravenous catheter.&#xD;
&#xD;
          -  A female subject is pregnant or breast-feeding.&#xD;
&#xD;
          -  The subject has active peptic ulcer disease or other potentially hemorrhagic&#xD;
             esophagitis/gastritis.&#xD;
&#xD;
          -  The subject has active immune thrombocytopenic purpura (ITP), autoimmune hemolytic&#xD;
             anemia (AIHA), or a history of being refractory to platelet transfusions (within 1&#xD;
             year prior to the first dose of study drug).&#xD;
&#xD;
          -  The subject has received any anti-cancer therapy including chemotherapy,&#xD;
             immunotherapy, radiotherapy, hormonal therapy (with the exception of hormones for&#xD;
             hypothyroidism, estrogen replacement therapy [ERT], anti estrogen analogs, agonists&#xD;
             required to suppress serum testosterone levels [e.g., LHRH, GnRH, etc.] for subjects&#xD;
             with prostate cancer if on a stable dose for at least 21 days prior to the first dose&#xD;
             of study drug), or any investigational therapy with 14 days prior to the first dose of&#xD;
             study drug, or has not recovered to less than a grade 2 clinically significant adverse&#xD;
             effect(s)/toxicity(s) of the previous therapy.&#xD;
&#xD;
          -  The subject has received an antibody therapy or other biologic (with the exception of&#xD;
             colony stimulating factors [G-CSF, GM-CSF] or erythropoietin) within 28 days prior to&#xD;
             the first dose of study drug.&#xD;
&#xD;
          -  The subject has consumed grapefruit or grapefruit products within 3 days prior to the&#xD;
             first dose of study drug.&#xD;
&#xD;
          -  The subject has received steroid therapy for anti-neoplastic intent within 7 days&#xD;
             prior to the first dose of study drug with the exception of inhaled steroids for&#xD;
             asthma, topical steroids, replacement/stress corticosteroids, or corticosteroids taken&#xD;
             as premedication for this study.&#xD;
&#xD;
          -  The subject has received aspirin or known CYP3A inhibitor (e.g., ketoconazole) within&#xD;
             7 days prior to the first dose of study drug.&#xD;
&#xD;
          -  The subject has undergone an allogeneic stem cell transplant.&#xD;
&#xD;
          -  The subject has received radio-immunotherapy within 6 months prior to the first dose&#xD;
             of study drug.&#xD;
&#xD;
          -  The subject has a history of hypersensitivity to docetaxel or other polysorbate 80&#xD;
             drugs.&#xD;
&#xD;
          -  The subject has tested positive for human immunodeficiency virus, HIV (due to&#xD;
             potential drug-drug interactions between anti-retroviral medications and navitoclax&#xD;
             (ABT-263), as well as anticipated navitoclax (ABT-263) mechanism based lymphopenia&#xD;
             that may potentially increase the risk of opportunistic infections and potential&#xD;
             drug-drug interactions with certain anti infective agents).&#xD;
&#xD;
          -  The subject has a significant history of cardiovascular (e.g., MI, thrombotic or&#xD;
             thromboembolic event in the last 6 months), renal, neurologic, psychiatric,&#xD;
             endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the&#xD;
             investigator would adversely affect his/her participating in this study. Questions&#xD;
             regarding inclusion of individual subjects should be directed to the Abbott Medical&#xD;
             Monitor or designee.&#xD;
&#xD;
          -  The subject exhibits evidence of other clinically significant uncontrolled&#xD;
             condition(s) including, but not limited to:&#xD;
&#xD;
               -  active systemic fungal infection;&#xD;
&#xD;
               -  A diagnosis of fever and neutropenia within 1 week prior to study drug&#xD;
                  administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mack Mabry, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 51982</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 44182</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 43962</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12844</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 20042</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 12845</name>
      <address>
        <city>Surrey</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Navitoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

